<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Simulations Plus, Inc.

    Simulations Plus, Inc.

    Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metab...

    Simulations Plus, Inc. is the leading developer...

    Filing Type:    PU
    Onconova Therapeutics, Inc.

    Onconova Therapeutics, Inc.

    Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused o...

    Onconova Therapeutics, Inc. is a Phase 3-stage ...

    Filing Type:    PU
    Option Care Health, Inc.

    Option Care Health, Inc.

    For more than 40 years, Option Care has been shaping the home infusion services in...

    For more than 40 years, Option Care has been sh...

    Filing Type:    PU
    Affimed Therapeutics

    Affimed Therapeutics

    At Affimed, we are committed to improving outcomes for patients with cancer. Our s...

    At Affimed, we are committed to improving outco...

    Filing Type:    PU
    Axonics Modulation Technologies, Inc.

    Axonics Modulation Technologies, Inc.

    Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) is a medical technology compan...

    Axonics Modulation Technologies, Inc. (NASDAQ:A...

    Filing Type:    PU
    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...

    Harpoon Therapeutics is a clinical-stage immuno...

    Filing Type:    PU
    OncoSec Medical Incorporated

    OncoSec Medical Incorporated

    OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...

    OncoSec Medical Incorporated is a clinical-stag...

    Filing Type:    PU
    BeyondSpring, Inc.

    BeyondSpring, Inc.

    Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...

    Headquartered in New York, BeyondSpring Inc. (B...

    Filing Type:    PU
    Celsion Corporation

    Celsion Corporation

    Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...

    Celsion Corporation is a fully integrated bioph...

    Filing Type:    PU
    ArQule, Inc.

    ArQule, Inc.

    ArQule is a biopharmaceutical company engaged in the research and development of t...

    ArQule is a biopharmaceutical company engaged i...

    Filing Type:    PU
    IDEAYA Biosciences, Inc.

    IDEAYA Biosciences, Inc.

    IDEAYA is an oncology-focused precision medicine company committed to the discover...

    IDEAYA is an oncology-focused precision medicin...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.